A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs) Meeting Abstract
| Authors: | Armand, P.; Brody, J.; Barr, P. M.; Shustov, A. R.; Moskowitz, A. J.; Kline, J. P.; Savage, K. J.; Kuruvilla, J.; Josephson, N. C.; Zinzani, P. L.; Salles, G. A.; Masood, A.; Ansell, S. M. |
| Abstract Title: | A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 413s |
| Language: | English |
| ACCESSION: | WOS:000404711505088 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS7576 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS7576 -- Source: Wos |
